fashion -WSS

fashion

author：fashion 2025-09-29 14:00:30 - browse：9

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Medical students need to learn the potent medicine of empathy

WSS

New research sheds light on how often breast cancer is overdiagnosed

Protect nursing home residents from future pandemics

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Biogen Alzheimer’s drug launch off to slow start

A disappointing year of Humira biosimilars

Pharma’s losing bet in New Jersey

hotspot

fashion

explore

Virginia high school admissions case could be legal follow

Unmasking the 'centricity' illusion in clinical trials

Novavax promises a turnaround & Lilly roils the obesity market

BioAge raises $170M for combination therapy with Zepbound

Novavax promises a turnaround & Lilly roils the obesity market

Decentralized clinical trials need collaboration to achieve wider use

Peter Hotez and the public health issue of online harassment

KalVista pill reduced swelling 'attacks' caused by genetic disease

Cancer drug shortages should be causing more outrage

New research sheds light on how often breast cancer is overdiagnosed

entertainment

Senators start work on Medicare physician payment reform

Industry veterans launch new biotech VC with $310M

Medicare threatens to cut off funding for HCA's Mission hospital

Hospitals need to get ahead of regulations on climate change

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Lawsuit challenges CMS nursing home minimum staffing rule

hotspot

Wikipedia

knowledge

hotspot